Mobidiag

About Mobidiag

Mobidiag, a Finnish-French biotechnology company, was established in 2000 by Mart Saarma to specialize in molecular diagnostics. A significant milestone occurred in 2013 when Mobidiag merged with Genewave SAS, a French developer of automated diagnostics platforms, and Amplidiag Oy, a Finnish company holding patents in gastrointestinal diagnostics. This merger created a multidisciplinary entity with expertise in diagnostic equipment, software, reagents, and test development. The company's trajectory was further shaped by Tuomas Tenkanen, who served as CEO. Tenkanen, with a background in engineering and a history in the biotechnology sector, including co-founding and selling Finnzymes to Thermo Fisher Scientific, brought valuable experience to Mobidiag. In April 2021, Hologic, Inc. announced its acquisition of Mobidiag for an enterprise value of approximately $795 million, a deal that was finalized in June 2021.

Mobidiag's business centers on developing and marketing polymerase chain reaction (PCR)-based molecular diagnostic solutions. The company serves laboratories of all sizes, from small and mid-sized labs to large central hospitals, addressing the acute care market. Its revenue model is based on providing automated diagnostic platforms and the accompanying disposable test cartridges and reagents. The business targets critical areas such as gastrointestinal infections, respiratory infections, antimicrobial resistance management, and healthcare-associated infections (HAIs). In 2020, the company generated approximately $42 million in revenue.

The company's core offerings are two automated molecular diagnostic platforms: Amplidiag® and Novodiag®. The Amplidiag® family is designed for high-volume screening in larger laboratories. In contrast, the Novodiag® platform is a tabletop solution for on-demand testing in small to mid-sized labs, providing results in about an hour. A key feature of the Novodiag® system is its combination of real-time PCR and microarray technologies, which allows for high-level multiplexing. This multiplexing capability enables the identification of multiple pathogens from a single sample, which streamlines laboratory workflows and delivers rapid, actionable results to clinicians for conditions that present with similar symptoms but can be caused by numerous organisms.